Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, will announce its results for the fourth quarter and full year ended 31 December 2012 on Thursday 7 February 2013 at 7.00am GMT/2.00am Eastern time. This will be followed by a presentation for financial analysts at 9.00am GMT/4.00am Eastern time, which can be seen live via webcast on the Smith & Nephew website at www.smith-nephew.com and available on the site archive shortly afterwards.
For those individuals who wish to dial into the call a listen-only service is available by calling +44 (0) 20 7138 0813 in the UK or +1 718 354 1359 in the US (passcode 3548180).
Enquiries
Investors/Analysts
Kim Gunthorp
Tel: +44 (0) 20 7401 7646
Smith & Nephew plc
Media
Charles Reynolds
Smith & Nephew plc
Tel: +44 (0) 20 7401 7646
Justine McIlroy
Brunswick
Tel: +44 (0) 20 7404 5959
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2011 were nearly $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in integrating acquired businesses, and disruption that may result from changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
◊Trademark of Smith & Nephew. Registered US Patent and Trademark Office.